Oncology Therapy Review

Patient Information

Name: William Scott **DOB:** June 18, 1967

Email: william.scott@example.com

Allergies: None

Medical Record Number: 334566

Appointment Details

Date: May 26, 2024 **Time:** 9:15 AM

Doctor: Dr. Emily Rodriguez, MD

Chief Complaint

Review of ongoing immunotherapy for melanoma.

History of Present Illness

William Scott is a 56-year-old male with Stage IV melanoma, diagnosed in December 2022. Currently receiving pembrolizumab. Reports increased energy and improved appetite.

Past Medical History

Hyperthyroidism

Medications

• **Pembrolizumab:** 200 mg IV every 3 weeks

• Methimazole: 10 mg PO BID

Review of Systems

• Constitutional: Improved energy, no weight loss

• Respiratory: No cough, no dyspnea

• Cardiovascular: No chest pain

• Gastrointestinal: No nausea, no vomiting

Physical Examination

• General: Appears healthy, no distress

• Vital Signs: BP 124/76, HR 68, RR 16, Temp 98.5°F

• Skin: No new lesions

- Chest/Lungs: Clear to auscultation
- Cardiovascular: Normal S1/S2, no murmurs

Assessment

- Stage IV melanoma, responding to pembrolizumab
- Hyperthyroidism, controlled

Plan

- 1. Continue pembrolizumab therapy.
- 2. Schedule PET-CT in 6 weeks to assess response.
- 3. Routine blood tests including thyroid function every 6 weeks.
- 4. Follow up in 6 weeks to review PET-CT and lab results.

Signed:

Dr. Emily Rodriguez, MD Oncologist, Vita Clinic emily.rodriguez@vitaclinic.com